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Introduction
Photodynamic Therapy (PDT) was first approved as established 
therapeutic method by the FDA for certain kinds of cancer in 1998. 
However, In view of the limitation of the penetration of light energy 
into tumor tissues [1,2],  the successful application from LED or 
coherent laser emission source of PDT has been mostly limited 
to superficial pathology or through invasive method which could 
approach to the pathology with unwanted side- effects. Ultrasound 
is a mechanical wave which could penetrate tissue excellently and 
safely without major attenuation of its energy [3,4]. Therefore, the 
potential medical application of ultrasound has been evaluated 
extensively and has led to the routine use of ultrasound for 
diagnostic imaging. Sonodynamic Therapy (SDT) has been widely 
researched to develop as a complementary or alternative therapy to 
PDT [5-10]. In SDT treatment, patients first ingest a sonosensitizer, 
an agent that can be activated by ultrasound. This agent is tailored 
to be activated through the use of low-intensity ultrasound energy 
producing a cascade of endogenous cytotoxic radicals. The therapy 
 
is thus similar to PDT, which is an attractive modality for cancer 
treatment with potential to focus the energy on tumor sites buried 
deep in tissues and to locally activate a preloaded sonosensitizer. 
The body transmits ultrasound energy much more efficiently than 
light energy, and this is a critical advantage when treating inside 
tumors and with minimal damage to peripheral healthy tissue. So 
far, many compounds were found to have sonodynamic activity [5-
13]. In recent years, a novel sonosensitizer was developed by the 
late Donald Burke, MD, of Advanced Technologies, Boston, USA. He 
named this Sonoflora 1™ (SF1). This agent is a chlorophyll derivative 
with very high sonodynamic as well as photodynamic activity. 
Embryonic zebra fish assay had showed SF1 has no evidence of 
toxicity [3]. Our animal studies demonstrate that SDT with SF1 
inhibits the growth of mouse S-180 sarcoma, even when the tumor 
is covered by a bone [4]. We had successfully used Sonodynamic and 
Photodynamic Therapy (SPDT) with SF1 and a portable ultrasound 
device in terminally ill breast cancer patients [14].
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Abstract 
Photodynamic Therapy (PDT) is a therapeutic treatment for certain kinds of tumors, approved by the FDA in 1998. Recent research data shows 
that a related procedure, Sonodynamic Therapy (SDT), is another new promising complementary method for cancer treatment. Here we report 
clinical results in an advanced pancreas cancer patient who was treated using a combination of Sonodynamic and Photodynamic Therapy (SPDT), 
along with conventional therapies. The patient was pathologically diagnosed with metastatic pancreas carcinoma (non-respectable advanced 
pancreas cancer) by the patient’s local oncology team. The advanced pancreas carcinoma had responded unsatisfactorily to conventional therapies. 
SPDT treatment involved using a new sensitizing agent Sonoflora a TM (SFa), which was administered sublingually; 12-hour latter, the patient 
was treated with a combination of light and ultrasound devices, and a low dosage of chemotherapy simultaneously as a whole body treatment 
(SPDT follows the chemotherapy cycle periodically). Patient had good partial responses. The results indicate that SPDT could be a promising new 
complementary therapeutic combination for the treatment of pancreas cancer.
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Here, we report initial clinical data using two new chlorophyll-
derived sono-photo-sensitizing agents (SFa and UF) along with 
a new equipment, supplied by EEC Biotech (Guangzhou) Co. for 
systemic SDT. The sensitizers SFa and UF were given to patients 
through lingual absorption on day one and day three. On Day two 
today four ozone treatment was given twice a day. The tumor area 
and the whole body were irradiated by ultrasound on day two and 
day four twice a day for 40mins each time, then by red LED light 
at 45mV/cm2 and 554 nm of wavelength for 30 minutes once a 
day. We used multiple ultrasound transducers within systemic 
SDT device, the tumor area and whole body was irradiated for 40 
minutes at 75% pulse, 1 MHz and 2.0 W/cm2. The second week 
the same treatment was repeated. One cycle of SPDT included two 
round treatments and a week free.
Case Presentation
The patient is female, at the age of 61. She went to the local 
hospital for medical examination for abdominal pain with jaundice 
for a month in November 2017. Examination indicated space 
occupying lesion in pancreatic head. CA19-9 was high. Local Doctor 
diagnosed pancreatic cancer. A stand was implanted in patient’s 
bile duct. Patient underwent chemotherapy of Gemcitabine for 
three months after her jaundice was gone. Patient then had severe 
digestive tract symptoms, bone marrow suppression grade IV, 
Rechecked CA199 dropped significantly. However, no tumor 
shrinkage was seen in original lesion in CT images. Patient had 
been on Abraxane+Gemcitabine for three months Since February 
2018, during which she was showed digestive tract symptoms and 
had bone marrow suppression as well. Rechecked CT scan showed 
progression and patient started to build up a large amount of 
ascites.
Surgery and radiation were not suitable for the patients as 
metastasis and location of the tumor in pancreatic head. Two types 
of chemo failed after three months treatment and no conventional 
therapy was available for option.
July 2018 after all the necessary tests, the patient came to our 
hospital for treatment, she started the first cycle of SPDT on July 25, 
2018, cooperating chemotherapy with targeted medicine Erlotinib 
150mg Po Qd +Xeloda 1.5g Po Bid D1-14+Oxaliplatin 80mg D3, 
50mg D10, assisting with 5 days of HIFU treatments. During the 
course, patient had Grade II of digestive symptoms, nausea and 
vomiting, which were attenuated after symptomatic treatment. 
Ascites reduced obviously after the first cycle treatment. Tumor 
marker dropped from 4289U/ml to 3038U/ml.
Second cycle of SPDT cooperating chemotherapy (same 
regimen as the first one). During this course, patient had mild 
nausea, no myelosuppression. Tumor marker CA199 after second 
cycle of SPDT dropped to 1873/ml and ascites reduced rapidly. 
Doctor’s assessment indicated “stable”.
Third and fourth cycles of SPDT started on September 05, 2018, 
continuing chemotherapy with Erlotinib 150mg Po Qd +Xeloda 1.0g 
in the morning and 1.5g in the afternoon D1-14+Oxaliplatin 80mg 
D3. Reduced the dosage of chemo’s for her Grade III nausea, with 
Grade I myelosuppression.
A review of PET/CT (Oct 15, 2018) compared with July 23, 
2018 before treatment.
A. Metabolism in the head of pancreas slightly rises, size of 
focal obviously narrows and the metabolism obviously reduced. 
Considered suppressed in most tumor activity after treatment 
(Figure 1). 
Figure 1: Head of pancreas.
B. Multiple lymph nodes around pancreas and retroperitoneal 
region, multiple metastatic tumor in liver, metabolism reduced 
compared with the former scan. Considered suppressed of 
activity after treatment (Figure 2).
Figure 2: Primary tumor in pancreas.
C. The fluid collection in pelvic and abdominal cavity 
reduced obviously (Figures 3&4).
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Figure 3: Fluid in pelvic and abdominal cavity.
Figure 4: Fluid in abdominal cavity and liver metastasis.
Discussion
SPDT protocol shows a potential promise over many years 
as a safe and well tolerated non-invasive treatment in advanced 
metastatic cancer. No adverse events were noted following 
administration of SFa and UF. The case did not have photosensitive 
dermatitis or rash. We used photo-diagnostic method with SFa 
and UF, were found that the sensitizer’s specific fluorescence was 
only seen on superficial tumor, nothing on the normal skin, which 
implying our sensitizers did selectively accumulate in tumor. 
Compared with conventional PDT, such as Photofrin II-PDT, SPDT 
had almost no photo-dermatitis, when we tried to irradiate with 
laser light locally at 300 J/cm2 energy 24 hours after taken the 
sensitizers. This further indicated the sensitizer’s high clearance 
from normal tissues. The experiment carried indicated the 
sensitizer eliminate from the normal organs really quick even in 
less than 12h, that is why we could apply the systemic SDT after 
12 hours administration of sensitizer. The new systemic SDT device 
has 153 ultrasonic heads on the bottom and upper ultrasonic device. 
Under computer control, every ultrasound head simultaneously 
emitted same ultrasound at 75% pulse, 1 MHz, and 2.0 W/cm2 for 
40 minutes twice a day for 2 days during the protocol. This may 
indicate ultrasounds used in this study may be strong enough to 
activate the sensitizer in primary or secondary tumor masses in 
whole body.
In this case, SPDT with SFa and UF was well tolerated. Unlike 
chemotherapy and radiation therapy, SPDT has almost no toxic 
effects, nor has it affected marrow and gastrointestinal function, 
or affect the important organs such as heart, lungs, liver, or kidney. 
Patient had metastases in the liver before the treatment, her ascites 
built up for large amount and her Performance Status (PS) score 
was 3, her PS score was 2. She could spend more time outside 
of her room. Her ascites, swollen legs and feet were improving 
remarkably. She could tolerate the chemotherapy well with grade 
1 adverse effect of the gastrointestinal reaction, and her liver and 
kidney function blood test showed no obvious changes after the 
combined therapies.
Pain in the tumor regions was the main side effect of SPDT and 
HIFU. Some patients have no pain in their liver but patients may 
feel the pain in the ultrasound bath tube. If the patient kept still 
in the ultrasound bath, the energy could accumulate in the deep 
organs, especially in the bone, which causes pain. The problem can 
be avoided by using pulsed ultrasound or remind patients slowly 
move in the water. SPDT-induced tumor breakdown can also induce 
local pain and make patients feel weak and tired, in our experience 
patients could recover soon in a few days. HIFU could also cause 
pain in the treatment area but this pain could be released in hours. 
HIFU could also help quick relief the pancreas cancer patients’ back 
pain after several times of HIFU therapy.
High intensity focused ultrasound which is a physical therapy 
has developed during the past 20 years [15]. It uses the ultrasonic 
waves with the function of penetration and focusing capability to 
form a high-calorie focal field on the tumor location where the 
depth less than 9cm. It makes the solid tumor protein coagulation 
and necrosis, then kill the target cells. At present, high intensity 
focused ultrasound has been widely used in the treatment of solid 
tumors. In recent years, high intensity focused ultrasound in the 
treatment of liver cancer has attracted more and more attention. 
The application of high intensity focused ultrasound become more 
and more common as a local palliative treatment of tumor, it has 
the advantages on safety, effectiveness and less side effects. We 
adopt the mature ultrasonic focusing knife combined with the new 
generation of sensitivity agent which can achieve better clinical 
efficacy in treating local tumor without systemic side effects. We 
found that the tumor has been shrunk obviously and metabolic 
activity has dropped after the combined treatment.
Possible cytotoxic mechanisms may include generation of 
sonosensitizer-derived radicals which initiates chain peroxidation 
of membrane lipids via peroxyl and/or alkoxyl radicals, the physical 
destabilization of the cell membrane by the sonosensitizer thereby 
rendering the cell more susceptible to shear forces and cavitation 
effects. Especially we administered the chemotherapy with the 
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SPDT simultaneously, ultrasound may enhance drug transport 
across the cell membrane [11,16,17].
In summary, SPDT with SFa and UF was well tolerated and had 
demonstrated significant therapeutic benefits for the patient with 
advanced pancreas cancer. There also appears to be a potential 
role for SPDT in adjuvant pancreas cancer treatment, considering 
that pancreas cancer has a low survival rate. There are some 
new targeted medicines and immunotherapies which have been 
used for other solid tumors but have not been used promisingly 
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